Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

PHASE3CompletedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

December 6, 2013

Primary Completion Date

September 12, 2016

Study Completion Date

May 2, 2019

Conditions
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Interventions
DRUG

Momelotinib

Momelotinib tablet administered orally once daily

DRUG

Ruxolitinib

Ruxolitinib tablets administered orally twice daily

DRUG

Placebo to match momelotinib

Placebo to match momelotinib tablets administered orally once daily

DRUG

Placebo to match ruxolitinib

Placebo to match ruxolitinib tablets administered orally twice daily

Trial Locations (114)

Unknown

Phoenix

Escondido

Stanford

Jacksonville

Atlanta

Chicago

Baltimore

Boston

St Louis

Durham

Seattle

Darlinghurst

Parkville

Saint Leonards

Brisbane

Herston

Adelaide

Bedford Park

Frankston

Melbourne

Perth

Vienna

Charleroi

Antwerp

Leuven

Liège

Pleven

Plovdiv

Rousse

Sofia

Varna

Edmonton

Vancouver

Hamilton

Toronto

Hradec Králové

Brno

Ostrava

Aalborg

Herlev

Pierre-Bénite

Toulouse

Le Kremlin-Bicêtre

Lens

Lille

Marseille

Nantes

Paris

Pessac

Villejuif

München

Leipzig

Dresden

Düsseldorf

Freiburg im Breisgau

Hamburg

Mainz

Mannheim

Budapest

Debrecen

Kaposvár

Afula

Ashkelon

Haifa

Jerusalem

Tel Aviv

Ōgaki

Kitaku Sapporo

Osaka

Ōsaka-sayama

Bunkyo-ku, Tokyo

Fukushima

Kumamoto

Matsuyama

Okayama

Maastricht

Nijmegen

Rotterdam

Utrecht

Poznan

Krakow

Lublin

Warsaw

Gdansk

Bialystok

Brzozów

Chorzów

Lodz

Arad

Brasov

Bucharest

Cluj-Napoca

Iași

Singapore

Seoul

Majadahonda

Pamplona

Badalona

Barcelona

Valencia

Zaragoza

Lund

Örebro

Stockholm

Uddevalla

Kaohsiung City

Leicester

London

Manchester

Newcastle upon Tyne

Oxford

Cardiff

Northern Ireland

Nottingham

All Listed Sponsors
lead

Sierra Oncology LLC - a GSK company

INDUSTRY

NCT01969838 - Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis | Biotech Hunter | Biotech Hunter